<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H3ED6D2B2285C44DC83EA6247BE4339B7" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5773 IH: Consumer Vaccine Safety and Protection Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-09-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5773</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230927">September 27, 2023</action-date><action-desc><sponsor name-id="P000599">Mr. Posey</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to remove certain liability protections for certain biological products and other drugs if the sponsor thereof fails to disclose to the public all non-exempt data within the biological product file or drug application, and for other purposes.</official-title></form><legis-body id="H0E357E12D7A2466F98E0C1CE9AD05389" style="OLC"><section id="HFA49AD3D512A4984A91C4BBB878B60FE" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Consumer Vaccine Safety and Protection Act of 2023</short-title></quote>.</text></section><section id="H101E657ED375445BA9E8BB988CC8B829"><enum>2.</enum><header>Disclosure of non-exempt data required for certain biological products and other drugs</header><text display-inline="no-display-inline">Section 319F–3 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6b">42 U.S.C. 247d–6b</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HA25E535052254686A389901487CEC2F3" display-inline="no-display-inline"><subsection id="HF5DED221D3E34BA094E5E598AF9272F9"><enum>(j)</enum><header>Disclosure of non-Exempt data required</header><paragraph id="H59CFD1E259A84544A20561F281964D84"><enum>(1)</enum><header>Covered products</header><text display-inline="yes-display-inline">In this subsection, the term <term>covered product</term> means a covered countermeasure that—</text><subparagraph id="H943CAB4F0D044A7992FCE489E533D123"><enum>(A)</enum><text display-inline="yes-display-inline">is a biological product or other drug; and</text></subparagraph><subparagraph id="HF28C853AE1C44A1BAF8A9E14F05C7143"><enum>(B)</enum><text display-inline="yes-display-inline">is authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act on or after the date of enactment of the <short-title>Consumer Vaccine Safety and Protection Act of 2023</short-title>, irrespective of whether the biological product or drug later receives approval or licensure under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act.</text></subparagraph></paragraph><paragraph id="H24805F92518F4C72AE34D47D47102B41"><enum>(2)</enum><header>Disclosure by sponsors</header><subparagraph id="H1E4D4E2DF6D84D1A97BAD7A564FD4B86"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subparagraph (C), the sponsor of a covered product shall disclose to the public, in an easily accessible location on the website of the sponsor of the covered product—</text><clause id="HB901522CCD53414FBC6430777EB0E350"><enum>(i)</enum><text>in the case of a biological product, all data and information available for public disclosure under section 601.51(e) of title 21, Code of Federal Regulations (or successor regulations); and</text></clause><clause id="H7F76374153BC4C4A943F5A579DFC7238"><enum>(ii)</enum><text>in the case of another drug, all data and information available for public disclosure under section 314.430 of title 21, Code of Federal Regulations (or successor regulations).</text></clause></subparagraph><subparagraph id="HD3BA21BC447E4C159EE89500C27B0F38"><enum>(B)</enum><header>Timing</header><text>The sponsor of a covered product shall, with respect to any data or information required to be disclosed by subparagraph (A), make the disclosure not later than 10 days after the later of—</text><clause id="HA89915A7F9BD4117A7947AA2259C14E9"><enum>(i)</enum><text display-inline="yes-display-inline">the date on which the Food and Drug Administration authorizes the emergency use of the covered product under section 564 of the Federal Food, Drug, and Cosmetic Act; and</text></clause><clause id="H07B6C1BD654F4B0D8B5B3DE3C3634415"><enum>(ii)</enum><text>the date on which the data or information becomes available to the sponsor.</text></clause></subparagraph><subparagraph id="HA693FC59B646451F88187B1891123C4A"><enum>(C)</enum><header>Exceptions</header><text display-inline="yes-display-inline">The disclosure requirement in subparagraph (A) does not apply with respect to—</text><clause id="H2B67D87A7B7B41D793231A80BB821699"><enum>(i)</enum><text display-inline="yes-display-inline">a trade secret or confidential commercial or financial information as defined in section 20.61 of title 21, Code of Federal Regulations (or successor regulations); or</text></clause><clause id="H409C58F4F4A64532A136655141225D57"><enum>(ii)</enum><text>personally identifiable information.</text></clause></subparagraph></paragraph><paragraph id="H37694ABFA9C74DD2867C9041826537A8"><enum>(3)</enum><header>Disclosure by HHS</header><subparagraph id="H1638F7D7FC09461788223A0ED15A2839"><enum>(A)</enum><header>In general</header><text>Subject to subparagraph (B), the Secretary shall—</text><clause id="HD6CBD67F1277449D8E668F6724960DF5"><enum>(i)</enum><text display-inline="yes-display-inline">not later than 10 days after the Food and Drug Administration authorizes the emergency use of a covered product under section 564 of the Federal Food, Drug, and Cosmetic Act or approves or licenses a covered product under section 505 of such Act or section 351 of this Act, disclose to the public, in an easily accessible location on the website of the Department of Health and Human Services, all data and information required by paragraph (2) to be disclosed by the sponsor of the product; and</text></clause><clause id="HCD2B2B23CDF343FBB9434D7E32EC31AA"><enum>(ii)</enum><text display-inline="yes-display-inline">not later than 30 days after receiving any additional such data and information, so disclose such data and information.</text></clause></subparagraph><subparagraph id="H596434C5A44E478F80B2909EE0946586"><enum>(B)</enum><header>Exception</header><text>The disclosure requirement in subparagraph (A) does not apply with respect to data and information exempted from disclosure by paragraph (2)(C).</text></subparagraph></paragraph><paragraph id="H65398F7C1FA2458982C4487737436B24"><enum>(4)</enum><header>Enforcement against sponsors for failure to disclose</header><subparagraph id="H21978A78EBBB4B4FB902A749328CFFE6"><enum>(A)</enum><header>Exclusion from definition of <quote>covered countermeasure</quote></header><text>Notwithstanding subsection (i)(1), a covered product is deemed to be excluded from the definition of a <quote>covered countermeasure</quote> for purposes of the provisions of this section (other than this subsection) and section 319F–4 if—</text><clause id="H9FD0A691092B41F0BC5FA3D1791DBE58"><enum>(i)</enum><text>the covered product is administered on or after the date of enactment of the <short-title>Consumer Vaccine Safety and Protection Act of 2023</short-title>; and</text></clause><clause id="H0C5963EADEE142F28A7F402477DA75F8"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor of the covered product is determined by the Secretary to have knowingly failed to make a disclosure required by paragraph (2) with respect to the covered product.</text></clause></subparagraph><subparagraph id="H06B68CE0FA35474EBFDEFFE95BA75855"><enum>(B)</enum><header>Ineligibility for FDA awards, funds, or other benefits</header><text display-inline="yes-display-inline">If the sponsor of a covered product is determined by the Secretary to have knowingly failed to make a disclosure required by paragraph (2) with respect to the covered product, such sponsor shall be treated as ineligible for the award of any grant, cooperative agreement, or loan or for any new grant of emergency use authorization, expanded access, or approval or licensure of any product under section 351 of this Act or any provision of the Federal Food, Drug, and Cosmetic Act so long as such sponsor continues to be in violation of such requirement.</text></subparagraph></paragraph><paragraph id="HFA2C71E5C5E049BCA15535EC5A30F6A9"><enum>(5)</enum><header>Enforcement against HHS for failure to disclose</header><text display-inline="yes-display-inline">A party injured by a covered product with respect to which the Secretary failed to carry out the Secretary’s duties under paragraph (3) may bring an action in the appropriate district court of the United States for appropriate relief, including damages.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

